|
GS185131: GO:0044699 single-organism process
|
|
GS187248: GO:0072359 circulatory system development
|
|
GS183514: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS183848: GO:0044260 cellular macromolecule metabolic process
|
|
GS186757: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS202082: GO:0051254 positive regulation of RNA metabolic process
|
|
GS164257: MP:0002085 abnormal embryonic tissue morphology
|
|
GS136704: systemic lupus erythmatosus suppressor 1 (Sles1, Published QTL Chr 17)
|
|
GS167566: MP:0005018 decreased T cell number
|
|
GS169127: MP:0002445 abnormal mononuclear cell differentiation
|
|
GS198685: GO:0048522 positive regulation of cellular process
|
|
GS170086: MP:0000703 abnormal thymus morphology
|
|
GS201949: GO:0044699 single-organism process
|
|
GS33995: Neocortex Gene expression correlates of blood ethanol concentration in mg/dl in Females & Males BXD
|
|
GS170089: MP:0000706 small thymus
|
|
GS208954: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS167687: MP:0011099 complete lethality throughout fetal growth and development
|
|
GS209028: GO:0000981 sequence-specific DNA binding RNA polymerase II transcription factor activity
|
|
GS185261: GO:0051254 positive regulation of RNA metabolic process
|
|
GS186526: GO:0005654 nucleoplasm
|
|
GS135590: P. chabaudi malaria resistance QTL 3 (Char3, Published QTL Chr 17)
|
|
GS203018: GO:0045935 positive regulation of nucleobase-containing compound metabolic process
|
|
GS190950: GO:0009059 macromolecule biosynthetic process
|
|
GS136392: organ weight 10 (Org10, Published QTL Chr 17)
|
|
GS164506: MP:0001698 decreased embryo size
|
|
GS181568: GO:0006357 regulation of transcription from RNA polymerase II promoter
|
|
GS168559: MP:0002421 abnormal cell-mediated immunity
|
|
GS178461: GO:0009987 cellular process
|
|
GS136833: trypanosome infection response 1 (Tir1, Published QTL Chr 17)
|
|
GS192624: GO:0043231 intracellular membrane-bounded organelle
|
|
GS135229: Angiostrongylus costaricensis nematode susceptibility 3 (Acsns3, Published QTL Chr 17)
|
|
GS186743: GO:0043227 membrane-bounded organelle
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS170108: MP:0003727 abnormal retinal layer morphology
|
|
GS181012: GO:0007423 sensory organ development
|
|
GS167996: MP:0002407 abnormal double-negative T cell morphology
|
|
GS193268: GO:0005575 cellular_component
|
|
GS135641: circadian photosensitivity 2 (Circp2, Published QTL Chr 17)
|
|
GS194039: GO:1901363 heterocyclic compound binding
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS196934: GO:0065008 regulation of biological quality
|
|
GS207797: GO:0030154 cell differentiation
|
|
GS167252: MP:0011100 complete preweaning lethality
|
|
GS207581: GO:0007275 multicellular organismal development
|
|
GS165028: MP:0002399 abnormal pluripotent precursor cell morphology/development
|
|
GS199273: GO:0043233 organelle lumen
|
|
GS136305: modifier of Yaa 2 (Myaa2, Published QTL Chr 17)
|
|
GS163271: MP:0006042 increased apoptosis
|
|
GS191019: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS205002: GO:0048856 anatomical structure development
|
|
GS163852: MP:0001544 abnormal cardiovascular system physiology
|
|
GS168334: MP:0002619 abnormal lymphocyte morphology
|
|
GS187887: GO:0080090 regulation of primary metabolic process
|
|
GS136509: particle-induced immune disfunction (Pidys, Published QTL Chr 17)
|
|
GS86494: Table S1: Hippocampus 17 K microarray data. [DRG]
|
|
GS165839: MP:0009701 abnormal birth body size
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS170358: MP:0001823 thymus hypoplasia
|
|
GS168389: MP:0001186 pigmentation phenotype
|
|
GS203054: GO:0048514 blood vessel morphogenesis
|
|
GS166858: MP:0000685 abnormal immune system morphology
|
|
GS178814: GO:0046982 protein heterodimerization activity
|
|
GS163965: MP:0011182 decreased hematopoietic cell number
|
|
GS166749: MP:0002221 abnormal lymph organ size
|
|
GS163956: MP:0011180 abnormal hematopoietic cell number
|
|
GS189669: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS163010: MP:0011181 increased hematopoietic cell number
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS126646: Carbon Tetrachloride interacting genes (MeSH:D002251) in CTD
|
|
GS206108: GO:2001141 regulation of RNA biosynthetic process
|
|
GS192017: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS166225: MP:0009850 embryonic lethality between implantation and placentation
|
|
GS194493: GO:0001944 vasculature development
|
|
GS191106: GO:0044464 cell part
|
|
GS177404: GO:0005737 cytoplasm
|
|
GS35902: Striatum Gene expression correlates of Handling induced convulsions 4 hrs after ethanol in Females & Males BXD
|
|
GS177265: GO:0048731 system development
|
|
GS207925: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS186227: GO:0090304 nucleic acid metabolic process
|
|
GS201251: GO:0044424 intracellular part
|
|
GS193238: GO:0031323 regulation of cellular metabolic process
|
|
GS168593: MP:0002088 abnormal embryonic growth/weight/body size
|
|
GS203908: GO:0016070 RNA metabolic process
|
|
GS167991: MP:0002401 abnormal lymphopoiesis
|
|
GS181893: GO:0048522 positive regulation of cellular process
|
|
GS170136: MP:0008083 decreased single-positive T cell number
|
|
GS204612: GO:0019222 regulation of metabolic process
|
|
GS188142: GO:0048856 anatomical structure development
|
|
GS210168: GO:0030098 lymphocyte differentiation
|
|
GS136226: mandible length 18 (Manln18, Published QTL Chr 17)
|
|
GS169287: MP:0005090 increased double-negative T cell number
|
|
GS136157: leishmaniasis resistance 1 (Lmr1, Published QTL Chr 17)
|
|
GS177862: GO:0001775 cell activation
|
|
GS209551: GO:0031981 nuclear lumen
|
|
GS164258: MP:0002084 abnormal developmental patterning
|
|
GS135462: bleomycin pulmonary fibrosis 1 (Bplpf1, Published QTL Chr 17)
|
|
GS194555: GO:0031974 membrane-enclosed lumen
|
|
GS135227: anticardiolipin antibody 1 (Acla1, Published QTL Chr 17)
|
|
GS164133: MP:0005076 abnormal cell differentiation
|
|
GS193414: GO:0044249 cellular biosynthetic process
|
|
GS197472: GO:0044451 nucleoplasm part
|
|
GS169962: MP:0001286 abnormal eye development
|
|
GS167833: MP:0001784 abnormal fluid regulation
|
|
GS135736: delta power in slow-wave sleep 3 (Dps3, Published QTL Chr 17)
|
|
GS178927: GO:0003705 RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity
|
|
GS169133: MP:0002442 abnormal leukocyte physiology
|
|
GS203607: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS83968: cocaine induced activation 13 (Cocia13, Published QTL, Chr 17)
|
|
GS163824: MP:0001259 abnormal body weight
|
|
GS197802: GO:0007423 sensory organ development
|
|
GS169114: MP:0004196 abnormal prenatal growth/weight/body size
|
|
GS167660: MP:0004200 decreased fetal size
|
|
GS168710: MP:0001648 abnormal apoptosis
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS163432: MP:0006069 abnormal retinal neuronal layer morphology
|
|
GS178922: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS187708: GO:0009893 positive regulation of metabolic process
|
|
GS135650: cocaine induced activation 13 (Cocia13, Published QTL Chr 17)
|
|
GS204232: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS84300: METH responses for body temperature (Published QTL, Chr 17)
|
|
GS136887: UVB induced immunosuppression 2 (Uvbi2, Published QTL Chr 17)
|
|
GS192876: GO:0030218 erythrocyte differentiation
|
|
GS191579: GO:0034101 erythrocyte homeostasis
|
|
GS135556: CD8 memory T cell subset 5 (Cd8mts5, Published QTL Chr 17)
|
|
GS169630: MP:0001785 edema
|
|
GS167039: MP:0003886 abnormal embryonic epiblast morphology
|
|
GS193937: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS205237: GO:0030217 T cell differentiation
|
|
GS135256: adenovirus induced hyperthyroidism 2 (Advh2, Published QTL Chr 17)
|
|
GS168063: MP:0000313 abnormal cell death
|
|
GS180156: GO:0065008 regulation of biological quality
|
|
GS164994: MP:0008533 abnormal anterior visceral endoderm morphology
|
|
GS136120: body length 9 (Lgth9, Published QTL Chr 17)
|
|
GS195643: GO:0003677 DNA binding
|
|
GS198572: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS169118: MP:0004198 abnormal fetal size
|
|
GS135861: femur breaking strength 4 (Fembrs4, Published QTL Chr 17)
|
|
GS136483: plasmacytoma susceptibility 5 (Pcyts5, Published QTL Chr 17)
|
|
GS195340: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS196808: GO:0032501 multicellular organismal process
|
|
GS186744: GO:0043226 organelle
|
|
GS182835: GO:0005622 intracellular
|
|
GS166438: MP:0002231 abnormal primitive streak morphology
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS206544: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS135331: autoimmune susceptibility in C57BL/6J and BALB/c 3 (Asbb3, Published QTL Chr 17)
|
|
GS182703: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS210178: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS204108: GO:0072358 cardiovascular system development
|
|
GS194133: GO:0005737 cytoplasm
|
|
GS198360: GO:0006357 regulation of transcription from RNA polymerase II promoter
|
|
GS203406: GO:0009653 anatomical structure morphogenesis
|
|
GS84301: ethanol conditioned taste aversion (Published QTL, Chr 17)
|
|
GS186790: GO:0006725 cellular aromatic compound metabolic process
|
|
GS167627: MP:0005460 abnormal leukopoiesis
|
|
GS136437: platelet-binding antibody-associated thrombocytopenia 1 (Pbat1, Published QTL Chr 17)
|
|
GS168683: MP:0000598 abnormal liver morphology
|
|
GS194111: GO:0097159 organic cyclic compound binding
|
|
GS199501: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS136265: modifier of mammary tumor progression 2 (Mmtp2, Published QTL Chr 17)
|
|
GS166437: MP:0002230 abnormal primitive streak formation
|
|
GS206329: GO:0060255 regulation of macromolecule metabolic process
|
|
GS163943: MP:0005201 abnormal retinal pigment epithelium morphology
|
|
GS135250: adiposity 18 (Adip18, Published QTL Chr 17)
|
|
GS180138: GO:0048872 homeostasis of number of cells
|
|
GS195199: GO:0005634 nucleus
|
|
GS193234: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS167500: MP:0000208 decreased hematocrit
|
|
GS136482: plasmacytoma susceptibility 4 (Pcyts4, Published QTL Chr 17)
|
|
GS136634: small effect CIA locus 8 (Secia8, Published QTL Chr 17)
|
|
GS189240: GO:2001141 regulation of RNA biosynthetic process
|
|
GS165386: MP:0001262 decreased body weight
|
|
GS135782: early growth QTL 5 (Egq5, Published QTL Chr 17)
|
|
GS186178: GO:0045935 positive regulation of nucleobase-containing compound metabolic process
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS166590: MP:0002873 normal phenotype
|
|
GS165535: MP:0005370 liver/biliary system phenotype
|
|
GS187343: GO:0006351 transcription, DNA-dependent
|
|
GS203369: GO:0005654 nucleoplasm
|
|
GS195571: GO:0046982 protein heterodimerization activity
|
|
GS187175: GO:0045321 leukocyte activation
|
|
GS185492: GO:0050789 regulation of biological process
|
|
GS136021: hematopoietic stem cell frequency regulator (Hscfr, Published QTL Chr 17)
|
|
GS181473: GO:0005488 binding
|
|
GS184445: GO:0044428 nuclear part
|
|
GS167714: MP:0002414 abnormal myeloblast morphology/development
|
|
GS208513: GO:0034101 erythrocyte homeostasis
|
|
GS180036: GO:0032501 multicellular organismal process
|
|
GS192345: GO:0010628 positive regulation of gene expression
|
|
GS196930: GO:0065007 biological regulation
|
|
GS200312: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS177859: GO:0045944 positive regulation of transcription from RNA polymerase II promoter
|
|
GS191150: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS166772: MP:0002596 abnormal hematocrit
|
|
GS164966: MP:0001724 abnormal extraembryonic endoderm formation
|
|
GS168685: MP:0009395 increased nucleated erythrocyte cell number
|
|
GS210170: GO:0030097 hemopoiesis
|
|
GS193227: GO:0030097 hemopoiesis
|
|
GS169205: MP:0003717 pallor
|
|
GS169389: MP:0002060 abnormal skin morphology
|
|
GS136429: pulmonary adenoma susceptibility 2 (Pas2, Published QTL Chr 17)
|
|
GS167542: MP:0001790 abnormal immune system physiology
|
|
GS135370: B.burgdorferi-associated arthritis 8 (Bbaa8, Published QTL Chr 17)
|
|
GS167326: MP:0002145 abnormal T cell differentiation
|
|
GS204746: GO:0080090 regulation of primary metabolic process
|
|
GS163601: MP:0002089 abnormal postnatal growth/weight/body size
|
|
GS165869: MP:0002138 abnormal hepatobiliary system morphology
|
|
GS201249: GO:0044428 nuclear part
|
|
GS136866: T cell receptor induced activation 3 (Tria3, Published QTL Chr 17)
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS185438: GO:0001568 blood vessel development
|
|
GS193991: GO:0048731 system development
|
|
GS198456: GO:0019438 aromatic compound biosynthetic process
|
|
GS163294: MP:0000218 increased leukocyte cell number
|
|
GS181667: GO:0019438 aromatic compound biosynthetic process
|
|
GS204107: GO:0072359 circulatory system development
|
|
GS165163: MP:0006205 embryonic lethality between implantation and somite formation
|
|
GS194088: GO:0003676 nucleic acid binding
|
|
GS188511: GO:0010468 regulation of gene expression
|
|
GS165527: MP:0005378 growth/size phenotype
|
|
GS35911: Striatum Gene expression correlates of Handling induced convulsions 4 hrs after ethanol in Males BXD
|
|
GS164448: MP:0005193 abnormal anterior eye segment morphology
|
|
GS178589: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS178813: GO:0046983 protein dimerization activity
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS184447: GO:0044424 intracellular part
|
|
GS169490: MP:0001306 small lens
|
|
GS193236: GO:0031326 regulation of cellular biosynthetic process
|
|
GS169777: MP:0002398 abnormal bone marrow cell morphology/development
|
|
GS191021: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS199499: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS203335: GO:0048513 organ development
|
|
GS188684: GO:0070013 intracellular organelle lumen
|
|
GS186740: GO:0043229 intracellular organelle
|
|
GS135877: femur geometry 14 (Fmgty14, Published QTL Chr 17)
|
|
GS196540: GO:0043565 sequence-specific DNA binding
|
|
GS163240: MP:0002364 abnormal thymus size
|
|
GS193225: GO:0030098 lymphocyte differentiation
|
|
GS166250: MP:0008247 abnormal mononuclear cell morphology
|
|
GS182475: GO:0043233 organelle lumen
|
|
GS188506: GO:0010467 gene expression
|
|
GS208012: GO:0044464 cell part
|
|
GS210212: GO:0005575 cellular_component
|
|
GS195291: GO:0006355 regulation of transcription, DNA-dependent
|
|
GS201239: GO:0046483 heterocycle metabolic process
|
|
GS84303: differences in cocaine responsiveness (Published QTL, Chr 17)
|
|
GS86916: Table S4: Cocaine Regulation of Dimethyl-K9 / K27 H3. [DRG]
provisional
|
|
GS205369: GO:0010468 regulation of gene expression
|
|
GS192073: GO:1901576 organic substance biosynthetic process
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS188762: GO:0009889 regulation of biosynthetic process
|
|
GS206623: GO:0050794 regulation of cellular process
|
|
GS197924: GO:0046649 lymphocyte activation
|
|
GS208060: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS184435: GO:0046483 heterocycle metabolic process
|
|
GS136943: weight 6 weeks QTL 11 (W6q11, Published QTL Chr 17)
|
|
GS168422: MP:0000716 abnormal immune system cell morphology
|
|
GS187370: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS163818: MP:0002722 abnormal immune system organ morphology
|
|
GS207015: GO:0042592 homeostatic process
|
|
GS136758: soft tissue heal 11 (Stheal11, Published QTL Chr 17)
|
|
GS164261: MP:0002081 perinatal lethality
|
|
GS186214: GO:0048518 positive regulation of biological process
|
|
GS194038: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS165612: MP:0002128 abnormal blood circulation
|
|
GS35351: Cerebellum Gene expression correlates of Mechanical Nociception - Tail Clip Test in Males BXD
|
|
GS166194: MP:0009931 abnormal skin appearance
|
|
GS163050: MP:0000260 abnormal angiogenesis
|
|
GS129089: bronchial hyperresponsiveness 3 (Bhr3 Published QTL Chr 17)
|
|
GS170366: MP:0000245 abnormal erythropoiesis
|
|
GS136962: weight adult 4 (Wta4, Published QTL Chr 17)
|
|
GS164515: MP:0001693 failure of primitive streak formation
|
|
GS177310: GO:1901360 organic cyclic compound metabolic process
|
|
GS167020: MP:0003956 abnormal body size
|
|
GS165616: MP:0002127 abnormal cardiovascular system morphology
|
|
GS135455: body weight 2 (Bodwt2, Published QTL Chr 17)
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS210180: GO:0031326 regulation of cellular biosynthetic process
|
|
GS169833: MP:0005380 embryogenesis phenotype
|
|
GS182834: GO:0005623 cell
|
|
GS205622: GO:0009889 regulation of biosynthetic process
|
|
GS163942: MP:0005200 abnormal eye pigment epithelium morphology
|
|
GS191151: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS170338: MP:0008801 abnormal erythroid progenitor cell morphology
|
|
GS209282: GO:0010628 positive regulation of gene expression
|
|
GS189460: GO:0060255 regulation of macromolecule metabolic process
|
|
GS197016: GO:0032991 macromolecular complex
|
|
GS178448: GO:0005634 nucleus
|
|
GS199635: GO:0005622 intracellular
|
|
GS195206: GO:0002520 immune system development
|
|
GS163591: MP:0005015 increased T cell number
|
|
GS168012: MP:0010832 lethality during fetal growth through weaning
|
|
GS136043: insulin dependent diabetes susceptibility 16 (Idd16, Published QTL Chr 17)
|
|
GS166553: MP:0005457 abnormal percent body fat
|
|
GS208061: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS178537: GO:0006355 regulation of transcription, DNA-dependent
|
|
GS196943: GO:0008152 metabolic process
|
|
GS122888: beta-Naphthoflavone interacting genes (MeSH:D019324) in CTD
|
|
GS202261: GO:0001568 blood vessel development
|
|
GS165244: MP:0010771 integument phenotype
|
|
GS196941: GO:0008150 biological_process
|
|
GS199634: GO:0005623 cell
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS124695: arsenic trioxide interacting genes (MeSH:C006632) in CTD
|
|
GS190893: GO:0030154 cell differentiation
|
|
GS166150: MP:0001577 anemia
|
|
GS170006: MP:0005602 decreased angiogenesis
|
|
GS168690: MP:0000596 abnormal liver development
|
|
GS136177: locomotor activity 2 (Loco2, Published QTL Chr 17)
|
|
GS163946: MP:0011106 partial embryonic lethality between implantation and somite formation
|
|
GS187045: GO:0016070 RNA metabolic process
|
|
GS201256: GO:0044422 organelle part
|
|
GS168151: MP:0001914 hemorrhage
|
|
GS162897: MP:0003984 embryonic growth retardation
|
|
GS210182: GO:0031323 regulation of cellular metabolic process
|
|
GS163026: MP:0000221 decreased leukocyte cell number
|
|
GS201431: GO:0005515 protein binding
|
|
GS26254: Cerebellum Gene expression correlates of Mechanical Nociception - Tail Clip Test in Females & Males BXD
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS209411: GO:0048869 cellular developmental process
|
|
GS166947: MP:0001683 absent mesoderm
|
|
GS186211: GO:0048514 blood vessel morphogenesis
|
|
GS187160: GO:0044707 single-multicellular organism process
|
|
GS168083: MP:0006413 increased T cell apoptosis
|
|
GS177548: GO:0048534 hematopoietic or lymphoid organ development
|
|
GS177761: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS190682: GO:0007275 multicellular organismal development
|
|
GS136861: "T cell receptor beta variable 4, control 1" (Trbv4c1, Published QTL Chr 17)
|
|
GS199267: GO:0043234 protein complex
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS181783: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS192981: GO:0001525 angiogenesis
|
|
GS193059: GO:0044446 intracellular organelle part
|
|
GS210181: GO:0031325 positive regulation of cellular metabolic process
|
|
GS168560: MP:0002420 abnormal adaptive immunity
|
|
GS209564: GO:0043231 intracellular membrane-bounded organelle
|
|
GS165811: MP:0009703 decreased birth body size
|
|
GS135576: cystic fibrosis lung disease 3 (Cfld3, Published QTL Chr 17)
|
|
GS136800: total body bone mineral density 7 (Tbbmd7, Published QTL Chr 17)
|
|
GS35593: Hippocampus Gene expression correlates of Morphine photocell counts minutes 165-180 in Females BXD
|
|
GS136903: ventral midbrain iron content 9 (Vmbic9, Published QTL Chr 17)
|
|
GS202080: GO:0051252 regulation of RNA metabolic process
|
|
GS208051: GO:0002521 leukocyte differentiation
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS170198: MP:0001614 abnormal blood vessel morphology
|
|
GS170138: MP:0008081 abnormal single-positive T cell number
|
|
GS168082: MP:0006412 abnormal T cell apoptosis
|
|
GS196916: GO:0048872 homeostasis of number of cells
|
|
GS204568: GO:0009893 positive regulation of metabolic process
|
|
GS163620: MP:0002086 abnormal extraembryonic tissue morphology
|
|
GS163297: MP:0000217 abnormal leukocyte cell number
|
|
GS193226: GO:0030099 myeloid cell differentiation
|
|
GS136400: organ weight 9 (Org9, Published QTL Chr 17)
|
|
GS204021: GO:0044707 single-multicellular organism process
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS184629: GO:0005515 protein binding
|
|
GS169603: MP:0001672 abnormal embryogenesis/ development
|
|
GS203525: GO:0043010 camera-type eye development
|
|
GS177843: GO:0002376 immune system process
|
|
GS169111: MP:0004197 abnormal fetal growth/weight/body size
|
|
GS135924: hepatocarcinogenesis in females 1 (Hcif1, Published QTL Chr 17)
|
|
GS163971: MP:0002092 abnormal eye morphology
|
|
GS170236: MP:0005452 abnormal adipose tissue amount
|
|
GS84302: differences in cocaine responsiveness (Published QTL, Chr 17)
|
|
GS169421: MP:0002447 abnormal erythrocyte morphology
|
|
GS180152: GO:0065007 biological regulation
|
|
GS186488: GO:0048513 organ development
|
|
GS165397: MP:0001265 decreased body size
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS135324: antibody response to human factor IX (Arfix, Published QTL Chr 17)
|
|
GS135763: experimental allergic encephalomyelitis susceptibility 5 (Eae5, Published QTL Chr 17)
|
|
GS194284: GO:0048534 hematopoietic or lymphoid organ development
|
|
GS166718: MP:0002169 no abnormal phenotype detected
|
|
GS166160: MP:0011092 complete embryonic lethality
|
|
GS196806: GO:0032502 developmental process
|
|
GS169173: MP:0006387 abnormal T cell number
|
|
GS203594: GO:0043226 organelle
|
|
GS136083: keratoconus 1 (Krcn1, Published QTL Chr 17)
|
|
GS205364: GO:0010467 gene expression
|
|
GS164022: MP:0008246 abnormal leukocyte morphology
|
|
GS210169: GO:0030099 myeloid cell differentiation
|
|
GS194586: GO:0002376 immune system process
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS170093: MP:0000259 abnormal vascular development
|
|
GS190949: GO:0009058 biosynthetic process
|
|
GS165537: MP:0005376 homeostasis/metabolism phenotype
|
|
GS182705: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS136378: obesity QTL 4 (Obq4, Published QTL Chr 17)
|
|
GS136773: SGC/Knj cross B6 QTL 3 (Sxbq3, Published QTL Chr 17)
|
|
GS204036: GO:0045321 leukocyte activation
|
|
GS167217: MP:0001325 abnormal retina morphology
|
|
GS136092: long bones 10 (Lbn10, Published QTL Chr 17)
|
|
GS203593: GO:0043227 membrane-bounded organelle
|
|
GS201265: GO:0009891 positive regulation of biosynthetic process
|
|
GS177308: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS190016: GO:0001654 eye development
|
|
GS182194: GO:0005667 transcription factor complex
|
|
GS210000: GO:0044446 intracellular organelle part
|
|
GS206897: GO:0001654 eye development
|
|
GS194605: GO:0001775 cell activation
|
|
GS135616: circulating hormone level QTL 8 (Chlq8, Published QTL Chr 17)
|
|
GS202316: GO:0050789 regulation of biological process
|
|
GS194087: GO:0003674 molecular_function
|
|
GS170351: MP:0006208 lethality throughout fetal growth and development
|
|
GS184461: GO:0009891 positive regulation of biosynthetic process
|
|
GS167098: MP:0001819 abnormal immune cell physiology
|
|
GS167963: MP:0008973 decreased erythroid progenitor cell number
|
|
GS177356: GO:0003674 molecular_function
|
|
GS178885: GO:0003677 DNA binding
|
|
GS203590: GO:0043229 intracellular organelle
|
|
GS209923: GO:0001525 angiogenesis
|
|
GS166450: MP:0011089 complete perinatal lethality
|
|
GS167321: MP:0003945 abnormal lymphocyte physiology
|
|
GS180001: GO:0048646 anatomical structure formation involved in morphogenesis
|
|
GS136686: skull morphology 25 (Skull25, Published QTL Chr 17)
|
|
GS177309: GO:1901363 heterocyclic compound binding
|
|
GS136479: periosteal circumference 4 (Pcir4, Published QTL Chr 17)
|
|
GS169128: MP:0002444 abnormal T cell physiology
|
|
GS196837: GO:0042110 T cell activation
|
|
GS188410: GO:0032774 RNA biosynthetic process
|
|
GS192471: GO:0048869 cellular developmental process
|
|
GS166578: MP:0003943 abnormal hepatobiliary system development
|
|
GS177754: GO:0001944 vasculature development
|
|
GS180166: GO:0008152 metabolic process
|
|
GS164446: MP:0005195 abnormal posterior eye segment morphology
|
|
GS192093: GO:0000981 sequence-specific DNA binding RNA polymerase II transcription factor activity
|
|
GS198991: GO:0005667 transcription factor complex
|
|
GS136909: vertebral morphology and mechanical traits 14 (Vmmt14, Published QTL Chr 17)
|
|
GS180673: GO:0044451 nucleoplasm part
|
|
GS203072: GO:0090304 nucleic acid metabolic process
|
|
GS180063: GO:0042110 T cell activation
|
|
GS166016: MP:0001324 abnormal eye pigmentation
|
|
GS170362: MP:0000717 abnormal lymphocyte cell number
|
|
GS177382: GO:0097159 organic cyclic compound binding
|
|
GS135592: P. chabaudi malaria resistance QTL 7 (Char7, Published QTL Chr 17)
|
|
GS195678: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS128599: Ethanol Induced Ataxia Chr#17
|
|
GS136942: weight 10 weeks QTL 12 (W10q12, Published QTL Chr 17)
|
|
GS84304: Hprt-ps1 (Published QTL, Chr 17)
|
|
GS169531: MP:0005391 vision/eye phenotype
|
|
GS163103: MP:0000003 abnormal adipose tissue morphology
|
|
GS205543: GO:0070013 intracellular organelle lumen
|
|
GS167795: MP:0001303 abnormal lens morphology
|
|
GS165809: MP:0002864 abnormal ocular fundus morphology
|
|
GS187751: GO:0019222 regulation of metabolic process
|
|
GS191144: GO:0002521 leukocyte differentiation
|
|
GS193237: GO:0031325 positive regulation of cellular metabolic process
|
|
GS195214: GO:0009987 cellular process
|
|
GS163934: MP:0001764 abnormal homeostasis
|
|
GS184452: GO:0044422 organelle part
|
|
GS204204: GO:0006351 transcription, DNA-dependent
|
|
GS180034: GO:0032502 developmental process
|
|
GS136562: radiation pulmonary fibrosis 1 (Radpf1, Published QTL Chr 17)
|
|
GS200648: GO:0044260 cellular macromolecule metabolic process
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS135781: early growth adjusted QTL 2 (Egaq2, Published QTL Chr 17)
|
|
GS170442: MP:0010866 abnormal prenatal body size
|
|
GS194602: GO:0045944 positive regulation of transcription from RNA polymerase II promoter
|
|
GS195683: GO:0003705 RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity
|
|
GS136685: skull morphology 24 (Skull24, Published QTL Chr 17)
|
|
GS185259: GO:0051252 regulation of RNA metabolic process
|
|
GS203642: GO:0006725 cellular aromatic compound metabolic process
|
|
GS188381: GO:0030217 T cell differentiation
|
|
GS181133: GO:0046649 lymphocyte activation
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS165539: MP:0005375 adipose tissue phenotype
|
|
GS209823: GO:0030218 erythrocyte differentiation
|
|
GS169334: MP:0009389 abnormal extracutaneous pigmentation
|
|
GS198263: GO:0005488 binding
|
|
GS187249: GO:0072358 cardiovascular system development
|
|
GS194040: GO:1901360 organic cyclic compound metabolic process
|
|
GS86932: Table S3: CORTEX 17K MICROARRAY [DRG]
|
|
GS135896: gastritis type A susceptibility locus 4 (Gasa4, Published QTL Chr 17)
|
|
GS84299: ethanol metabolism rate (Published QTL, Chr 17)
|
|
GS190067: GO:0018130 heterocycle biosynthetic process
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS169609: MP:0001674 abnormal triploblastic development
|
|
GS129074: alloantigen response 1 (Alan1 Published QTL Chr 17)
|
|
GS205266: GO:0032774 RNA biosynthetic process
|
|
GS165243: MP:0010770 preweaning lethality
|
|
GS166535: MP:0010865 prenatal growth retardation
|
|
GS136549: proteinuria 2 (Ptnu2, Published QTL Chr 17)
|
|
GS179777: GO:0043565 sequence-specific DNA binding
|
|
GS194267: GO:0043170 macromolecule metabolic process
|
|
GS210357: GO:0044249 cellular biosynthetic process
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS164247: MP:0001680 abnormal mesoderm development
|
|
GS178453: GO:0002520 immune system development
|
|
GS135644: cerebral malaria susceptibility in CBA/N (Cmcs, Published QTL Chr 17)
|
|
GS168270: MP:0002435 abnormal effector T cell morphology
|
|
GS182469: GO:0043234 protein complex
|
|
GS195570: GO:0046983 protein dimerization activity
|
|
GS206953: GO:0018130 heterocycle biosynthetic process
|
|
GS203057: GO:0048518 positive regulation of biological process
|
|
GS167589: MP:0005016 decreased lymphocyte cell number
|
|
GS190124: GO:0042592 homeostatic process
|
|
GS194499: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS169081: MP:0011186 abnormal visceral endoderm morphology
|
|
GS180164: GO:0008150 biological_process
|
|
GS177357: GO:0003676 nucleic acid binding
|
|
GS177531: GO:0043170 macromolecule metabolic process
|
|
GS167505: MP:0008762 embryonic lethality
|
|
GS186677: GO:0043010 camera-type eye development
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS169829: MP:0005385 cardiovascular system phenotype
|
|
GS196772: GO:0048646 anatomical structure formation involved in morphogenesis
|
|
GS167575: MP:0005013 increased lymphocyte cell number
|
|
GS177214: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS180236: GO:0032991 macromolecular complex
|
|
GS186562: GO:0009653 anatomical structure morphogenesis
|
|
GS207858: GO:0009059 macromolecule biosynthetic process
|
|
GS136260: male hybrid sterility QTL 1 (Mhstq1, Published QTL Chr 17)
|
|
GS165375: MP:0005459 decreased percent body fat
|
|
GS136372: obesity QTL 19 (Obq19, Published QTL Chr 17)
|
|
GS164262: MP:0002080 prenatal lethality
|
|
GS163560: MP:0008037 abnormal T cell morphology
|
|
GS164511: MP:0001697 abnormal embryo size
|
|
GS167307: MP:0002925 abnormal cardiovascular development
|
|
GS177813: GO:0031974 membrane-enclosed lumen
|
|
GS184218: GO:0071704 organic substance metabolic process
|
|
GS192610: GO:0031981 nuclear lumen
|
|
GS166156: MP:0011096 complete embryonic lethality between implantation and somite formation
|